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Abstract
The p38 MAPK signaling pathway has been proposed as a critical mediator of the therapeutic effect of several antitumor
agents, including cisplatin. Here, we found that sensitivity to cisplatin, in a system of 7 non-small cell lung carcinoma
derived cell lines, correlated with high levels of MKK6 and marked activation of p38 MAPK. However, knockdown of MKK6
modified neither the response to cisplatin nor the activation of p38 MAPK. Deeper studies showed that resistant cell lines
also displayed higher basal levels of MKK3. Interestingly, MKK3 knockdown significantly decreased p38 phosphorylation
upon cisplatin exposure and consequently reduced the response to the drug. Indeed, cisplatin poorly activated MKK3 in
resistant cells, while in sensitive cell lines MKK3 showed the opposite pattern in response to the drug. Our data also
demonstrate that the low levels of MKK6 expressed in resistant cell lines are the consequence of high basal activity of p38
MAPK mediated by the elevated levels of MKK3. This finding supports the existence of a regulatory mechanism between
both MAPK kinases through their MAPK. Furthermore, our results were also mirrored in head and neck carcinoma derived
cell lines, suggesting our observations boast a potential universal characteristic in cancer resistance of cisplatin. Altogether,
our work provides evidence that MKK3 is the major determinant of p38 MAPK activation in response to cisplatin and, hence,
the resistance associated with this MAPK. Therefore, these data suggest that the balance between both MKK3 and MKK6
could be a novel mechanism which explains the cellular response to cisplatin.
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Introduction
Cisplatin (cDDP) and its derivates are between the most used
drugs in cancer therapy, although the frequent development of
resistance to the drug is one of its major limitations [1]. Among the
several pathologies currently treated with cDDP, non-small cell
lung carcinoma (NSCLC), a subtype of lung cancer, is one of the
most challenging, due to the high ratio of refractory patients to the
current therapy (for a review see [2]). Nonetheless, new
approaches have been proposed to overcome cDDP resistance,
such as the use of glytazonas or copper chelators [3–5], that that
are aimed to improve cDDP based therapy, allowing more
selective use of the drug and avoiding some of the side effects. The
main target of cDDP is the DNA molecule, where the drug
induces several types of damages -mainly inter and intra catenaries
crosslinks- which prevent cell growth (for a review [6]). Resistance
to cDDP has been suggested to involve the dysfunction of several
genes which are major determinants of DNA repair mechanism,
such as p53, ERCC1 or BRCA1, and indeed some of these have
already been proposed as markers for patient outcome in cDDP
based therapy [7–9]. In addition to these molecules, several
signaling pathways have also been implicated in cDDP resistance
including the MAPK (Mitogen Activated Protein Kinase) family
[10]. In this regard, one of the member of the MAPK family, p38
MAPK, has been demonstrated to be a key player in the cellular
response to cDDP, and therefore in cancer therapy [11]. In fact,
previous reports showed how this signaling pathway is implicated
in cDDP resistance [12] and how it is connected to molecules
critical in tumor growth and the response to cDDP, such as p53 or
c-Abl [13,14] and more recently with the epidermal growth factor
receptor (EGFR), which has indeed become a new target in lung
cancer therapy [15,16]. Furthermore, it has been demonstrated
that MKP1, a phosphatase linked to several MAPK, including p38
MAPK, is implicated in the cellular response to cDDP in a
NSCLC derived cell line [17]. Interestingly, both natural
activators of p38 MAPK, the MAPK kinases (MAPKK) MKK6
and MKK3, show a very high structure similarity and are in fact
activated both in vivo and in vitro by the same stimuli, including
cDDP, TNF and UV [12,18]. However, one of the few differences
between both MAPKKs, is that MKK6 is regulated at the
transcriptional level by p38 MAPK activity [19], suggesting the
existence of a regulatory mechanism between the MAPK and this
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connected with cancer development (for a review [20]) and in
the particular case of lung cancer seems to be a critical protein in
the control of stem and progenitor cells [21]. In fact, the existence
of hyperactivation of this MAPK in lung cancer samples has been
reported [22], although so far no definitive link has been
established between p38 MAPK and patient outcome [23].
Therefore, the identification of new markers within the pathway
could be extremely useful to validate the role of p38 MAPK
signaling network as a biomarker in lung cancer and its therapy.
Here, we present evidence that MKK3, but not MKK6, is the
critical player in p38 MAPK signaling-associated cDDP resistance
in NSCLC derived cell lines. Our data also demonstrate that the
interplay between both MAPKKs is crucial for p38 MAPK
activation in response to cDDP and proposes that the imbalance
between MKK6/MKK3 could be a potential biomarker in
NSCLC.
Materials and Methods
Cell lines
Non-small lung cancer cells (H23, Hop62, H157, H226, H460,
H661 and H1299) and Head and neck squamous cell carcinoma
cells (HN12, HN19, HN26 and HN30) were maintained in
DMEM (Invitrogen, Carlsbad, CA) supplemented with 10% FCS
plus antibiotics (Biowhittaker, Verviers, Belgium). Cells were
maintained in 5% CO2 and 37uC. H460 and H1299 were
purchased from ATCC (LGC promochem, Barcelona, Spain).
H23, Hop62, H157, H226 and H661 cell lines were kindly
provide by Dr. R. Pio (Department of Biochemistry, School of
Sciences. University of Navarra, Pamplona, Spain) [24]. HN 12,
19, 26 and 30 cell lines were kindly provided by Dr. S. Gutkind
(NIDCR, NIH,MD, USA) [25].
Western blotting and immunoprecipitation procedures
Cells were treated and collected in lysis buffer (25 mM HEPES
pH 7.5, 0.3 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 1% Triton
X-100, 0.1% SDS, 0.5% deoxycholic acid, 20 mM B-glycero-
phosphate) plus protease and phosphatase inhibitors (2 mg/ml
leupeptin, 2 mg/ml aprotinin, 1 mM PMSF and 0.1 mM
Na3VO4). Then, the indicated amount was loaded onto 8–10%
SDS-Page and blotted against the different antibodies. In the cases
of immunoprecipitation assays, extracts were washed and then,
soluble fraction was incubated with the indicated antibody (1 mg/
sample for 2 hr), incubated for 45 min in the presence of protein
G (gamma Bind Sepharose, Amersham) and then washed 3 times
in the same lysis buffer. Antibody detection was achieved by
enhanced chemiluminescence (Amersham Pharmacia, Uppsala,
Sweden) by film exposure or by using. Protein quantification was
performed using BCA Protein Assay Kit (Pierce, Rockford, IL)
following manufacturer instruction. Tubulin or total p38 MAPK
were used as an internal loading control. Quantification of western
blot was estimated by densitometryc analysis of filters by using
WCIF Image J. software. The values (given as arbitrary units) were
normalized taking into consideration the internal loading control
of each sample. Results show a representative blot out of 3 with
nearly identical results.
Treatment, chemicals and antibodies
Antibodies against activated forms of p38 MAPK and MKK3/6
as well as total MKK6 were from Cell Signaling Technologies
(Beverly, MA). Antibodies against total p38 MAPK and MKK3
were from Santa Cruz Biotechnology. UV irradiation was
performed at 120 mJ, using a UV-Stratalinker 1800 (Stratagene)
and collected 30 min after UV exposure. cDDP was purchased
from Ferre Farma (Barcelona, Spain) and prepared freshly before
use.
RNA interference assays
Plasmid for lentivirus (PLKO) containing shRNA for MKK3
and MKK6 were from Sigma Aldrich (catalog number
NM_002756 and NM_002578 respectively). Lentivirus produc-
tion, by using 293T cells, and infections were performed as
previously described [26]. 48 h after infection cells were exposed
to puromycin (1,75 mg/ml for H157 and 1,25 mg/ml for H460)
during 3 days for the generation of stable shRNA-expressing cell
lines We selected the best performing shRNA for further analysis
as judged for functional interference with endogenous levels of the
target proteins by Western blotting. siRNA against MKK3 was
purchased from Thermo Scientific-Dharmacon (ON-TARGET-
plus SMART pool L-003509-00-0005). Cells were transfected and
60 hr later were tested for endogenous expression of MKK3 and
MKK6 by qRT-PCR.
Viability assays
Viability was evaluated by the crystal violet method [12]. Cells
were seeded 24-hr prior drug treatment at 4610
4 cells/well.
Colorant was recovered using 1% acetic acid and optical density
was evaluated at 590 nm. Values were referred to untreated
controls. Data are the average of at least 3 independent
experiments performed in triplicates cultures.
RNA isolation, reverse transcription and real-time
quantitative PCR
Total RNA was obtained with the Qiagen RNA isolation kit,
following the manufacturer protocol. The isolated RNA was
subsequently treated with DNase (Promega, Madison, WI) to
remove any contaminating genomic DNA. The integrity of RNA
was always checked by running an aliquot in an agarose gel.
Reverse transcription was performed using 1 mg of DNase-treated
RNA in 20 ml of reaction volume (Fermentas, Glen Burnie, MD).
Samples were stored at 20uC until their utilization. Changes in the
mRNA expression of MKK6/MKK3 were examined by real-time
quantitative PCR using an ABIPrism 7000 Sequence Detection
System (Applied Biosystems, Foster City, CA). cDNA (5 mlo f
diluted reverse transcription product) was amplified using SYBR1
Green PCRMaster Mix (Applied Biosystems) in the presence of
primer oligonucleotides specific for MKK6, MKK3 and GADPH.
The PCR conditions were as follows: 95uC for 10 min, followed by
40 cycles consisting of 95uC for 15 sec and 60uC for 1 min. The
quantification was performed by the comparative cycle threshold
method, using the GADPH RNA expression level as internal
control. Primers for all target sequences were designed using the
computer Primer Express software program specially provided
with the 7000 Sequence Detection System (Applied Biosystems,
Foster City, CA). In all the cases, only one amplification product
was obtained. Chosen PCR primers were as follows: MKK6 sense
59-GGCCCCTGAAAGAATAAACCC-39, antisense 59-CGAAG-
GATGGCCAACTCAATC-39; MKK3 sense 59-CGGCTGC-
AAGCCCTACAT, antisense 59- CTCCAGACGTCGGACTT-
GACA-39; GADPH sense 59-TCGTGGAAGGACTCAT-
GACCA-39 antisense 59-CAGTCTTCTGGGTGGCAGTGA-39.
Data analysis
Results are represented as mean 6 SD of at least three
independent experiments performed in triplicate. Statistical
analysis was performed using the GraphPad Prism 5.00 software.
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significance of differences was indicated in figures by asterisks as
follows: *P,0.1, **P,0.05 and ***P,0.001.
Results
Sensitivity to cDDP correlates with p38 MAPK activation
In order to further study the role of p38 MAPKa (referred to
from now on as p38 MAPK) activation in response to cDDP, we
used an experimental model comprised of 7 NSCLC (Hop62,
H157, H460, H661, H226, H23 and H1299) and challenged them
with cDDP. All cell lines were exposed to the indicated doses of
cDDP during 24 (data not shown) or 48 hours (Fig. 1A) and
viability was evaluated by crystal violet method. As it is shown,
different levels of intrinsic resistance to the drug were observed.
Next, phosphorylation of p38 MAPK in response to cDDP
exposure was tested (Fig. 1B). Interestingly not all cell lines were
able to significantly activate the kinase. While Hop62, H157,
Figure 1. Lack of p38 MAPK activation correlates with resistance to CDDP. A) Seven NSCLC cell lines were treated with the indicated doses
of cDDP during 48 hours and viability was evaluated by the crystal violet method. Survival was referred to untreated cells. Bars indicate standard
deviation (SD). B) All cell lines were exposed to the indicated doses of cDDP for 2 hours. Then samples were collected and 50 mg of the total cell
lysate (TCL) were used to evaluate the p38MAPK phosphorylation levels by western blotting. Membranes were re-blotted against p38 as loading
control.
doi:10.1371/journal.pone.0028406.g001
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of p38 MAPK in response to cDDP, H226, H23 and H1299 were
more resistant and exhibited little response, suggesting a
correlation between p38 MAPK activation capability and the
response to cDDP.
MKK6 correlates with cDDP sensitivity but is not
responsible for cDDP-mediated p38 MAPK activation
The lack of p38 MAPK activation could be explained, among
other possibilities, by a defect in its direct upstream activators, the
MAPKKs. As one of the main activators of p38 MAPK in
response to several stimuli in vitro and in vivo [18], we decided to
explore MKK6.This MAPKK was studied at the protein and
RNA levels by WB and Q-PCR respectively in our NSCLC cell
panel (Fig. 2A). Remarkably, we observed a clear correlation
between MKK6 levels, cDDP-mediated p38 MAPK activation
and sensitivity to the drug. Conversely, lower levels, almost
undetectable, were observed in resistant cell lines in which cDDP
was unable to induce phosphorylation of p38 MAPK. This result
suggests that the lack of MKK6 expression could explain the
associated chemoresistance mediated by deficient p38 MAPK
activation. To investigate if MKK6 levels are responsible for
cDDP response, we use an shRNA to decrease MKK6 expression
in two of the cell lines with high expression. For this purpose,
H157 (Fig. 2B) and H460 (Fig. S1) were infected with a lentiviral
vector coding for shRNA against MKK6 or a control vector and
viability in response to cDDP was then evaluated (Fig. 2C).
Surprisingly, MKK6 diminution did not affect cDDP response.
Moreover, p38 MAPK activation in response to cDDP was
evaluated in these cells and similar activation trend was found in
both control and interfered cells (Figs. 2D and S1). Thus, these set
of results indicated that MKK6 is not responsible of p38 MAPK
activation in response to cDDP, excluding this MAPKK in p38
MAPK-associated cDDP chemoresistance.
Resistant cell lines display high levels of MKK3 which
correlates with high basal activity of p38 MAPK
All previous evidence supports a lack of involvement of MKK6
in the response to cDDP. Therefore, we next asked if the other
main activator of p38 MAPK, MKK3, could be implicated in
the selective cDDP-mediated-activation of p38 MAPK and the
resistance to this drug observed in our model of NSCLC derived
cell lines. To investigate this possibility, MKK3 levels were
evaluated in all cell lines by WB and Q-PCR (Fig. 3A), showing
significant and opposite pattern to MKK6 at both protein and
RNA levels (Fig. 2A). Resistant cell lines showed higher levels of
MKK3 than sensitive ones but nonetheless were unable to
activate p38 in response to cDDP. Taking this fact into account,
we explored the capability of cDDP to induce activation of
this MAPKK in both sensitive and resistant cell lines. There-
fore, we challenged four of the cell lines, two sensitive (H157,
H460) and two resistant (H23 and H1299), and examined
MKK3 activation (Fig. 3B). Interestingly, cells with high levels of
MKK3 showed an elevated phosphorylation in the absence of
stimuli but then poor activation of this particular MAPKK in
response to cDDP, while sensitive cell lines, with low levels,
showed a more than 3 fold increase in MKK3 activation in
response to cDDP. This result indicated that although sensitive
cell lines express low levels of this MAPKK, cDDP can efficiently
activate the MKK3-p38 MAPK signaling axis, suggesting that
this MAPKK is a key player in the activation of p38 MAPK and
the associated chemoresistance. To corroborate this hypothesis,
we used a genetic-based approach whereby siRNA against
MKK3 was used in a sensitive cell line (H157). As shown
(Fig. 3C), specific knockdown of MKK3 almost completely
blocked p38 MAPK activation, demonstrating the critical role of
MKK3 in the p38MAPK activation mediated by cDDP. In
addition, to further study the role of MKK3 in cDDP-resistance,
we evaluated the response to the drug in both sensitive cell lines
(H157 and H460) stably expressing an MKK3-targeted shRNA
(Figs. 3D and S2). Remarkably, the diminution of MKK3 levels
rendered a more resistant phenotype, increasing the survival to
approximately 30% when compared to cells infected with an
shRNA control (Fig. 3D), as well as a marked decrease in
activation of the pathway in response to cDDP (Fig. 3E). In
summary, this set of experiments supports the crucial role of
MKK3 in p38 MAPK activation by cDDP and the associated
chemoresistance.
MKK3 controls MKK6 levels in NSCLC derived cell lines
through activation of p38 MAPK
In light of our previous findings which show an opposite
expression pattern of both MAPKKs in our NSCLC experimental
model, we decided to explore the molecular basis of differential
expression for MKK6/MKK3. In this regard, p38MAPK has
been previously demonstrated to be a potent regulator of MKK6
RNA levels in mouse embryonic fibroblasts (MEF) [19]. To
evaluate the influence of the p38 MAPK phosphorylation in the
regulation of MKK6 levels in a tumorigenic context, basal levels of
active p38 MAPK were evaluated. Interestingly, we observed a
marked correlation between intrinsic activation of p38 MAPK and
MKK3 levels (Fig. 4A and Fig. 3A) that exhibited an inverse
correlation with MKK6 (Fig. 2A). Therefore, to investigate the
contribution of p38 MAPK basal activity in the regulation of
MKK6 levels, we measured the RNA levels of this MAPKK in the
presence of SB203580, a potent inhibitor of p38 MAPK activity
[27]. As it is shown in Fig. 4B, the presence of SB203580 increased
MKK6 RNA levels in resistant cells (H23 and H1299) cells which
possess high basal levels of phosphorylated p38 MAPK, while
barely affecting its levels in sensitive cells (H157 and H460) cells
which have low levels of basal p38 MAPK activation. To more
fully support our observation, we used an RNA interference
approach. Remarkably, knockdown of MKK3 by siRNA in the
resistant cell line H1299, which has high levels of MKK3,
rendered an increase in MKK6 protein and RNA levels (Fig. 4C).
In summary, this set of results strongly suggests that activation of
p38 MAPK through MKK3 controls MKK6 levels in NSCLC
(Fig. 5).
MKK3-p38 MAPK signaling axis is also a major
determinant of cellular response to cDDP in Head and
Neck Squamous Cell Carcinoma derived cell lines
We have demonstrated that MKK3 is a key player in cDDP-
mediated p38 MAPK activation and its associated cellular
resistance in NSCLC. However, we aimed to examine whether
our model was applicable to other pathologies such as head
and neck squamous cell carcinoma (HNSCC), where cDDP
is also a critical therapeutic agent [28]. To this end, a panel
of 4 cell lines derived from different oral tumors was used
(HN12, HN19, HN26 and HN30). First, we evaluated viability
in response to cDDP and found varying sensibility to the drug,
in a similar way to NSCLC (Fig. 6A). Next, we studied the
capacity of cDDP to activate the p38 pathway in these HNSCC
derived cell lines. For this purpose, cells were exposed to different
doses of cDDP and activation of p38 was evaluated (Fig. 6B).
While HN19 and HN30 were more sensitive and showed a
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were more resistant and exhibited only moderate activation.
Next, we evaluated MKK3 and MKK6 levels in our HNSCC
cell line panel. Remarkably, as observed for NSCLC derived
cell lines, resistant cell lines (HN12 and HN26) exhibit low levels
of MKK6 and high levels of MKK3, while sensitive cell lines
(HN19 and HN30) display high levels of MKK6 and low levels of
MKK3 (Fig 6C). Hence, to complete this set of experiments, we
evaluated intrinsic p38 MAPK activation levels. As expected,
resistant cell lines (HN12 and HN26) exhibited higher basal
phosphorylation levels than intermediate and sensitive cell lines
(HN30 and HN19, respectively) (Fig. 6D). In summary, all this
data support our previous results in NSCLC, suggesting the
potential use of MKK6/MKK3 as biomarker in cisplatin based
therapy and confirming our proposed model also for HNSCC
(Fig. 5).
Figure 2. MKK6 expression level correlates with sensitivity to cDDP. A) Upper panel. Expression levels of endogenous MKK6 were evaluated
in all NSCLC lines using 200 mg of the TCL. For Tubulin detection 30 mg TCL were used. Lower panel. MKK6 mRNA levels were evaluated by Q-PCR.
Figure shows relative MKK6 mRNA levels referred to H23cell line. B) H157 cells were infected with lentivirus carrying an empty vector (shRNAC) or a
shRNA against MKK6 (shRNAMKK6). Upper panel. 100 mg of each cell lines TCL were used to evaluate MKK6 levels by WB. Tubulin was used as loading
control (30 mg TCL). Lower panel. ShRNA-induced mRNA diminution was also evaluated by Q-PCR. C) Both, shRNAC and shRNA MKK6 expressing cells
were treated with the indicated doses of cDDP during 48 h. Survival was referred to untreated cells. Bars mean SD. D) H157 shRNA expressing cells
were treated and analysed as in 1B. Levels of active p38 were quantified and referred to p38 total level.
doi:10.1371/journal.pone.0028406.g002
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PLoS ONE | www.plosone.org 5 December 2011 | Volume 6 | Issue 12 | e28406Figure 3. MKK3 mediates p38 MAPK dependent resistance to cDDP in NSCLC. A) MKK3 levels were analysed by WB (left panel) and Q-PCR
(right panel) as in 2A. B) H23, H1299 (resistant/ high MKK3 levels), h157 and H460 (sensitive/low MKK3 levels) were exposed to cDDP (40 mg/ml). 2 h
later, samples were collected and 1 mg of protein (H23, H1299) or 2 mg (H157, H460) were used to inmunoprecipitate endogenous MKK3.
Inmunocomplexes were blotted against active MKK3. Equivalent amounts of TCL were used to analyze tubulin. C) H157 cells were transfected either
with a siRNA C or a siRNA against MKK3 by duplicate. 60 h later mRNA MKK3 levels were evaluated by Q-PCR in a set of plates. The other set was split
1/2 and 24 hour later (left panel) cells were treated with cDDP at the indicated dose during 2 h. Cells were collected and active p38 MAPK levels were
evaluated. Membranes were re-blotted against p38 as a loading control. D) H157 cells were infected with lentivirus coding for a shRNA against MKK3
MKK3 Mediates Cisplatin Resistance in NSCLC
PLoS ONE | www.plosone.org 6 December 2011 | Volume 6 | Issue 12 | e28406Discussion
In this report we reveal the critical role of the p38 MAPK
network in the response to cDDP in NSCLC cell lines. Moreover,
we provide mechanistic insights into the resistance to cDDP
through the altered balance between MKK3/MKK6, and
propose the use of these MAPKK as new biomarkers.
With regards to the p38 MAPK signaling pathway, our data
demonstrates a unique intrinsic control that has not been
described for other MAPK signaling pathways. In its regulation,
one of its main MAPKKs (MKK3) is able to control another
(MKK6) through the activation of the p38 MAPK, supporting
previous observations [19]. It is interesting to note that our data
are obtained from transformed cell lines while the previous
observations were made in the context of non-transformed cells
(MEF) from the KO mice for p38 MAPK, suggesting that our
proposed mechanism is one of the natural ways by which the p38
MAPK signaling pathway can be deregulated in cancer. In this
regard, p38 MAPK has been proposed to act as a tumor
suppressor by sensing ROS levels [29]. In fact, the lack of p38
MAPK phosphorylation correlates with an increase in tumorigen-
esis in several different contexts [18,21,29] suggesting that the
activation of the pathway should be opposite to transformation (for
a review [20,30]). However, other evidence supports a role for p38
MAPK in survival and proliferation in both normal and
transformed cells (for revision see [31]). In our experimental
model we found a significant disparity in the basal levels of active
p38 MAPK, meaning that constitutive activation of the p38
MAPK is not a universal phenomena in cancer, or at least
NSCLC. Whether this differing status of p38 MAPK, due to an
imbalance between MKK6/MKK3, might be implicated in the
genesis of NSCLC or in other types of tumors, as well as other
or a shRNA C and stable cell lines were generated like in 2B. Left panel. MKK3 mRNA levels were evaluated by Q-PCR in control and interfered cell
lines. Right panel. Stable shRNA expressing cells were processed as in 2C.(*P,0.1, **P,0.05). E) Stable shRNA expressing cells were treated and
analysed as in 1B. Levels of active p38 were quantified and referred to p38 MAPK total level.
doi:10.1371/journal.pone.0028406.g003
Figure 4. MKK3-mediated p38 MAPK activation controls MKK6 expression level. A) 50 mg of TCL was used to evaluate active p38 MAPK
basal levels in the 7 NSCLC derived cell lines panel. Membrane was then re-blotted against total p38 and tubulin as loading controls. B) H157, H460
(sensitive/ high MKK6 levels), H23 and H1299 (resistant/low MKK6 levels) were exposed to 10 mM SB203580 during 36 h and MKK6 mRNA levels were
evaluated by Q-PCR. The inhibitor was renovated every 12 h. C) H1299 cells were transfected with a siRNA targeting MKK3 and 72 hour later MKK3
and MKK6 levels were evaluated by WB (upper panel) using 100 ug of TCL. mRNA levels were evaluated by Q-PCR at 60 hours post transfection
(lower panel).
doi:10.1371/journal.pone.0028406.g004
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further studied.
Our data reinforce the idea that p38 MAPK is a major player in
cDDP resistance [12,32]. In addition, our report introduces a new
concept concerning the role of p38 MAPK in cDDP resistance.
Here, we demonstrate that the inability of cDDP to activate p38
MAPK correlates with chemoresistance and this resistance is a
consequence of basal hyperactivation of the pathway. Interesting-
ly, ovarian cell lines with acquired resistant to cDDP, generated by
co-culture with the drug, showed elevated basal activation levels of
p38 MAPK [15], as well as in the case of resistant human
keratinocytes obtained with the same protocol (Galan-Moya and
Sanchez Prieto, unpublished observations). In light of our finding,
we can state that constitutive activation of the pathway seems to be
a natural mechanism of resistance associated with p38 MAPK.
This possibility is particularly important considering that no
genetic/epigenetic mechanisms (eg, mutations, variation in gene
copy number, LOH, methylation of promoters, etc.) has been
described so far for p38 MAPK. It’s noteworthy that several
screenings in yeast and eukaryotic cells have proposed key
molecules in the DNA damage response –vg. BRAC1, BRCA2
or ATR- as critical mediators in cDDP response [33] and, indeed,
some of them has been connected with the p38 MAPK signaling
pathway in response to several antitumor agents, including cDDP,
doxorubicin and 5-Fluorouracil [34,35]. Nonetheless, other
molecules implicated in this signaling pathway, such as ATF3
[36] and MKP1, which has been related to both ‘‘de novo’’ and
acquired resistance to cDDP in ovarian and lung cancer models
[17,37] should be considered in the final role of p38 MAPK in
cDDP resistance.
Another remarkable conclusion from this report is the
differential roles of MKK3 and MKK6 in the control of the p38
MAPK signaling pathway in response to cDDP. Of note, several
reports support the existence of a connection between p38 MAPK
Figure 5. Balance between MKK6 and MKK3 mediates p38 MAPK associated resistance to cisplatin. Upper panel: In the absence of
stimuli (left), sensitive cells display high basal levels of MKK6 and low basal levels of MKK3 which maintain a normal basal activity of p38 MAPK. When
cells are exposed to cDDP (right), the existing molecules of MKK3 are phosphorylated and then they are able to activate p38 MAPK, provoking the
death of the cells. Lower panel: In basal conditions (left), resistant cells express elevated levels of MKK3 which is indeed intrinsically phosphorylated.
As a consequence, resistant cells show an aberrant basal activity of p38 MAPK which is controlling MKK6 by decreasing its RNA levels. As
consequence of the constitutive activation of MKK3, cells are unable to respond to cDDP treatment (right), surviving after exposure to the drug.
doi:10.1371/journal.pone.0028406.g005
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others DNA damaging agents, such as ionizing radiation [15,38].
However, it has been also shown how inhibition of ASK1, a
MAPKKK of the p38 MAPK signaling pathway, affect MKK3 in
the apoptotic response to cDDP [39]. In the present work, we
demonstrate that the activation of p38 MAPK in response to
cDDP appears to be connected to the basal expression/activity of
MKK3, which controls basal levels of active p38 MAPK,
explaining why overactivation of both MAPKK is not possible,
since one regulates the levels of the other. The specific role of
MKK3 in the response to cDDP in NSCLC model is not unique.
Indeed , several reports have already shown that certain stimuli
can activate biological response depending exclusively on MKK3,
as in the case of selenite [40], hyperglycaemia induced by low
doses of streptozotocin [41] or in the case of TGF-b1 [42,43].
Furthermore, in some cases it has been proven that the activation
Figure 6. Basal p38 MAPK activation and MKK3 levels correlates with cDDP resistance in HNSCC derived cell lines. A) 4 HNSCC derived
cell lines were treated with the indicated doses of cDDP during 48 hours. Survival was referred to untreated cells. Bars indicate standard deviation
(SD). B) All cell lines were exposed to the indicated doses of cDDP for 2 h. Then, samples were collected and 50 mg of the total cell lysate TCL were
used to evaluate the p38MAPK phosphorylation levels. Membranes were re-blotted against p38 as loading control. C) 100 mg of TCL was used to
evaluate MKK6 and MKK3 protein levels. Tubulin was used as loading control. D) 50 mg of TCL were use to estimate levels of basal phosphorylation
p38 MAPK and total p38 MAPK expression levels.
doi:10.1371/journal.pone.0028406.g006
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properties of tumors, as is the case for gliomas or HNSCC [44,45].
Thus, in spite of apparent redundancies between both MAPKK
reported in some cases, our data support that there are some
biological processes in which they display differential roles, as we
have demonstrated here for cDDP resistance in NSCLC derived
cell lines.
Finally our work proposes that the balance between MKK6/
MKK3 could be used as a reporter for p38 MAPK activity and,
therefore, as a putative new biomarker in cancer, particularly in
NSCLC. In addition to being a major intermediary in the response
to cDDP, p38 MAPK is also implicated in some of the side effects
provoked by cDDP such as nephrotoxicity [46]. Consequently,
evaluation of the status of this signaling pathway is of interest for
determining the likelihood of both chemoresistance and cDDP-
associated side-effects. In this regard, there is little evidence of the
potential role of this signaling pathway as a biomarker in either
lung or head and neck cancers [22,23,45]. As we have
demonstrated here, the chemoresistance observed in both NSCLC
and HNSCC is due to a lack of activation of the pathway in
response to cDDP, indicating that the ideal situation to validate
p38 MAPK signaling pathway as a biomarker would be collecting
fresh samples before and after treatment, which together with
technical challenges (biopsies must be properly collected to
preserve phosphorylation) reduce the feasibility of measuring
phosphorylated p38 MAPK levels as a biomarker. However, our
data indicates that constitutive hyperactivation of the pathway
mediates chemoresistance and the expression levels of MKK6/
MKK3 are a suitable readout of p38 MAPK activity. Therefore,
evaluation of both MAPKK could be a way to estimate
chemoresistance without the necessity to evaluate phosphoryla-
tion, thereby simplifying the detection of the p38 MAPK status.
Hence both MAPKK (MKK6/MKK3) could be included in the
growing list of markers aimed to predict the outcome to cDDP,
such as ERCC1 or BRAC1 (for a review [47]). In addition to this,
new therapies based on antibodies- or pharmacologically-mediat-
ed inhibition of EGFR have been proposed for NSCLC [48].
Now, several evidences support a decisive role for p38 MAPK
signaling pathways in the biology of EGF receptor [16,49–51].
Therefore , our observation about p38 MAPK signaling pathway
in the cellular response to cDDP, could be also be involved in these
novel and selective therapies, that could account for the future
personalized therapy based on EGFR status as well as downstream
molecules as K-Ras [52]. Furthermore, p38 MAPK could be a
novel convergence point in NSCLC, considering that cDDP and
EGRF based therapies seem to be interrelated [53,54].
In summary, our data provides new insights into the task of the
p38 MAPK pathway in cDDP resistance. This effect is mediated
through constitutive activation of the pathway in which MKK3
appears to be the key protein, while MKK6-dependent signaling is
almost marginal. Whether these observations could be applicable
to other pathologies is currently being studied, as well as putative
proteins that potentially regulate the MKK3-p38 MAPK axis.
Supporting Information
Figure S1 Effect of MKK6 interference in H460 cells.
H460 cells were infected with lentivirus carrying an empty vector
(shRNAC) or a shRNA against MKK6 (shRNAMKK6). A)
ShRNA-induced mRNA diminution was evaluated by Q-PCR as
in H157 cell line. B) shRNAC and shRNA MKK6 expressing cells
were treated with the indicated doses of cDDP during 48 h.
Survival was referred to untreated cells. Bars mean SD. C) shRNA
expressing cells were treated and analysed as in Figure 1B. Levels
of active p38 MAPK were quantified and referred to p38 MAPK
total level.
(TIF)
Figure S2 Effect of MKK3 interference in H460 cells.
H460 cells were infected with lentivirus carrying an empty vector
(shRNAC) or a shRNA against MKK3 (shRNAMKK3). A)
shRNAC and shRNA MKK3 expressing cells were treated with
the indicated doses of cDDP during 48 h. Survival was referred to
untreated cells. Bars mean SD. B) ShRNA-induced mRNA
diminution was evaluated by Q-PCR as in H157 cell line. C)
shRNA expressing cells were treated and analysed as in Figure 1B.
Levels of active p38 MAPK were quantified and referred to p38
MAPK total level.
(TIF)
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